Welcome to Multibagg AI
Log in to access personalized features
IRIS
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Research powered by GOALZEN CAPITAL SERVICES PRIVATE LIMITED · SEBI Research Analyst INH000013448
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Discovery themes featuring this stockBearish
3
Neutral
3
Bullish
8
Bearish
35
Neutral
3
Bullish
8
Bearish
32
Neutral
0
Bullish
0
Bearish
3
Neutral
3
Bullish
8
Bearish
3
Neutral
3
Bullish
8
Bearish
32
Neutral
0
Bullish
0
Bearish
32
Neutral
0
Bullish
0
Bearish
32
Neutral
0
Bullish
0
Mercury Laboratories Limited, established in 1962, is a pharmaceutical company specializing in medicinal drugs and formulations. Incorporated as a private limited company in 1982, it later transitioned to a publicly listed entity in 1992.
The company consistently generates profits and pays dividends, indicating robust financial health and shareholder value.
Mercury Laboratories has a long-standing presence in the pharmaceutical industry, highlighting its stability and experience.
The company's transformation from a partnership firm to a public limited company showcases strategic business development over the decades.
Pharmaceuticals & Biotechnology
Pharmaceuticals
88 Cr
Low Risk
20.0
34.8
1.2
1.5
928.50
620.55
Sales CAGR
Profit CAGR
ROE
ROCE
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
136.40 | 94 Cr | -78.85 | 20.42 | 0.00 | 67.65 | -85.76 | -4.24 | ||
6.87 | 93 Cr | 21.88 | 1.19 | 0.00 | 6.03 | 8.35 | 3.45 | ||
44.99 | 90 Cr | 8.02 | 1.12 | 1.11 | 14.17 | 19.07 | 12.95 | ||
68.06 | 90 Cr | 43.74 | 1.92 | 0.00 | 2.17 | 5.12 | 2.74 | ||
731.05 | 88 Cr | 21.04 | 1.51 | 0.48 | 8.32 | 10.75 | 5.27 | ||
277.50 | 86 Cr | -38.80 | 1.26 | 0.00 | -4.86 | -2.57 | -1.78 | ||
60.00 | 83 Cr | 10.43 | 0.91 | 4.17 | 9.18 | 13.14 | 6.39 | ||
| Median: 7 Co. | — | 68.06 | 90 Cr | 10.43 | 1.26 | 0.00 | 8.32 | 8.35 | 3.45 |
Mercury Laboratories Ltd (MERCURYLAB) is currently trading at 731.05 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Mercury Laboratories Limited, established in 1962, is a pharmaceutical company specializing in medicinal drugs and formulations. Incorporated as a private limited company in 1982, it later transitioned to a publicly listed entity in 1992. The company consistently generates profits and pays dividends, indicating robust financial health and shareholder value. Mercury Laboratories has a long-standing presence in the pharmaceutical industry, highlighting its stability and experience. The company's transformation from a partnership firm to a public limited company showcases strategic business development over the decades.
Over the past 52 weeks, Mercury Laboratories Ltd has traded between a low of ₹620.55 and a high of ₹928.50. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Mercury Laboratories Ltd has a market capitalization of approximately 87.73. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Mercury Laboratories Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 19.98 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 87.73 Cr, Mercury Laboratories Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Mercury Laboratories Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Mercury Laboratories Ltd is 19.98. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
